Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2025 / Mar / Retinal Cell Death Protection
Retina Research & Innovations Anterior Segment Refractive Anterior Segment

Retinal Cell Death Protection

Remote preconditioning in mouse model shows promise in protecting against retinal cell death

By The Ophthalmologist 3/4/2025 1 min read

Share

A study published in Investigative Ophthalmology & Visual Science has highlighted the potential of remote preconditioning to protect retinal cells from damage following retinal detachment (RD). The research, conducted at the University of Michigan’s Kellogg Eye Center, investigated whether prior injury to one eye (i.e., caused by retinal detachment) could potentially confer protective effects on the contralateral retina.

Preconditioning, a process where exposure to a mild injury induces resistance to subsequent damage, has been explored in various organs across medical literature, including the heart and the brain. This study extends the concept to retinal health by examining whether detachment in one eye can precondition the other against future injury.

Using a mouse model, the researchers induced RD in the right eye at different time intervals before detaching the left retina. Their subsequent analysis revealed that prior RD in one eye provided temporary protection to the contralateral retina, reducing cell death markers and inflammatory responses. The effect was most pronounced when preconditioning occurred one to three days before the second RD, but this effect diminished after seven days.

Notably, researchers observed reduced caspase-3 cleavage, a key indicator of apoptosis, in the preconditioned retinas. Additionally, the expression of inflammatory cytokines – such as TNF-alpha and CXCL10 – was significantly lower in preconditioned retinas compared to non-preconditioned ones, suggesting an anti-inflammatory protective mechanism.

The authors say that the study provides compelling evidence that remote preconditioning could serve as a novel therapeutic approach to mitigate RD-induced retinal damage, and that, by leveraging the body’s innate protective mechanisms, clinicians might be able to reduce retinal damage and preserve vision in these at-risk patients.

About the Author(s)

The Ophthalmologist

More Articles by The Ophthalmologist

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: